Sutro Biopharma, Inc. (STRO) Institutional Ownership

Ownership Summary

Sutro Biopharma, Inc. (NASDAQ:STRO) showed up in the 13F filings of 61 institutional investors as of December 2025.

• They owned 66.9% of outstanding stock in December 2025, up from 63.1% the prior quarter.
• They increased total shares held in STRO by 1858.92% quarter over quarter, and investors in Sutro Biopharma decreased 50.41% from a year ago.
• Activity in STRO broke down as 58 buyers, 1 sellers, and 2 unchanged among 61 total holders.
• Altogether, these fund groups held 5.68Mn shares in STRO by December 2025, up by 5.39Mn shares quarter on quarter, and down 877.81K shares year over year.
• Affinity Asset Advisors, LLC is the top holder of Sutro Biopharma as of December 31, 2025, with 748.38K shares representing 8.82% of outstanding stock.
• The largest buyers of Sutro Biopharma for the quarter ending December 2025 were Affinity Asset Advisors, LLC (748.38K), Kynam Capital Management, LP (479.59K), MILLENNIUM MANAGEMENT LLC (418.2K), VANGUARD GROUP INC (375.79K), ACADIAN ASSET MANAGEMENT LLC (337.95K).
• Top sellers of STRO stock for the quarter ending December 2025 included EverSource Wealth Advisors, LLC (14).
• Per Business Quant, the top 10 investors in STRO for the quarter ending December 2025 include Affinity Asset Advisors, LLC (748.38K), Kynam Capital Management, LP (479.59K), MILLENNIUM MANAGEMENT LLC (418.2K), VANGUARD GROUP INC (375.79K), ACADIAN ASSET MANAGEMENT LLC (337.95K), Velan Capital Investment Management LP (312.0K), Merck & Co., Inc. (272.35K), Vestal Point Capital, LP (243.0K), BALYASNY ASSET MANAGEMENT L.P. (230.05K), Samsara BioCapital, LLC (204.5K).